Background Among patients with a proximal vessel occlusion in the anterior circulation, 60
to 80% of patients die within 90 days after stroke onset or do not regain functional …

Background Endovascular therapy is increasingly used after the administration of intravenous
tissue plasminogen activator (t-PA) for patients with moderate-to-severe acute ischemic …

Background Patients with transient ischaemic attack (TIA) or minor stroke are at high
immediate risk of stroke. The optimum early treatment options for these patients are not known. …

Background Nerinetide, an eicosapeptide that interferes with post-synaptic density protein
95, is a neuroprotectant that is effective in preclinical stroke models of ischaemia-reperfusion. …

Rationale The Interventional Management of Stroke (IMS) I and II pilot trials demonstrated
that the combined intravenous (iv) and intraarterial (ia) approach to recanalization may be …

Background In animal models of ischaemic stroke, 25% albumin reduced brain infarction and
improved neurobehavioural outcome. In a pilot clinical trial, albumin doses as high as 2 g/…

ESCAPE is a prospective, multicenter, randomized clinical trial that will enroll subjects with
the following main inclusion criteria: less than 12 h from symptom onset, age > 18, baseline …

Background and Purpose— High-dose human albumin (ALB) is robustly neuroprotective in
rodent stroke models. A phase I dose-escalation study was conducted to assess the safety of …

Background: Identification of therapies to prevent severe COVID-19 remains a priority. We
sought to determine whether hydroxychloroquine treatment for outpatients with SARS-CoV-2 …

Importance The benefits of endovascular thrombectomy (EVT) are time dependent. Prior
studies may have underestimated the time-benefit association because time of onset is …